SystImmune Tech Stack
Immuno-oncology biotech using AI-driven antibody design and protein modeling
SystImmune develops bi-specific, tri-specific, and antibody-drug conjugate therapeutics targeting solid tumors, with a tech stack revealing a shift toward computational drug discovery. The company runs AlphaFold, ProteinMPNN, and LLaMA alongside traditional biotech instrumentation (UPLC, HPLC, Leica microscopy), and is actively building scalable ML models and a computational protein design pipeline — signaling a move from pure bench biology toward AI-assisted target identification and therapeutic design. Hiring velocity is accelerating with research roles dominating (32 of 65 filled), but a notable leadership gap in senior biostatistics and quality functions suggests growing complexity in data and regulatory workflows.
Tech Stack 29 technologies
What SystImmune Is Building
◆Challenges
- Scaling hr practices
- Ensuring data integrity and regulatory compliance
- Technology transfer from research to manufacturing
- Identifying novel drug targets
- Design next-generation therapeutics
- Expanding recruiting capacity
- Data cleaning and reporting for new drug discovery
- Integration of analytical workflows
- Managing clinical supplies
- Tracking subject recruitment
▲Active Projects
- Immuno-oncology discovery/preclinical projects
- Scalable interpretable ml model development
- Technology transfer to clinical manufacturing
- Initial growth phase recruiting
- Onboarding and culture building initiatives
- Computational protein design pipeline
- Sop development
- Therapeutic design
- Ihc assay & cdx development
- Ai-driven therapeutic discovery pipeline
Hiring Activity
Department
Seniority
Notable leadership hires: Analytical Director, Biostatistics Director, Head of Quality
